1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by Sales Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Adoption for Novel Therapeutics
4.1.2. Restraints
4.1.2.1. Complications Associated with the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Patent Analysis
5.8. Volume Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Cutaneous Mastocytosis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Maculopapular Cutaneous Mastocytosis (Urticaria Pigmentosa)
7.2.4. Diffuse Cutaneous Mastocytosis
7.2.5. Mastocytoma of Skin (Solitary Mastocytoma)
7.2.6. Telangiectasia Macularis Eruptiva Perstans
7.3. Systemic Mastocytosis
7.3.1. Indolent Systemic Mastocytosis
7.3.2. Smoldering Systemic Mastocytosis
7.3.3. Systemic Mastocytosis with Another Blood or Bone Marrow Disorder
7.3.4. Aggressive Systemic Mastocytosis
7.3.5. Mast Cell Leukemia
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Antihistamines*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. H1 Antihistamines
8.2.4. H2 Antihistamines
8.3. Leukotriene Modifiers
8.4. Mast Cell Stabilizers
8.4.1. Cromolyn Sodium
8.4.2. Ketotifen
8.5. Topical Corticosteroids
8.6. Oral Steroids
8.7. Bisphosphonates
8.8. Injectable Epinephrine
8.9. Chemotherapy
8.9.1. Cladribine
8.9.2. Imatinib
8.9.3. Others
8.10. Allogeneic Hematopoietic Stem Cell Transplant (Bone Marrow Transplant)
8.11. Osteoporosis Therapy
8.12. Others
9. By Sales Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.1.2. Market Attractiveness Index, By Sales Channel
9.2. Distribution Channel*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Hospital Pharmacies
9.2.4. Retail Pharmacies
9.2.5. Online Pharmacies
9.3. End-User
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Dermatology Clinics
9.3.4. Research and Academic Centers
9.3.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Mylan N.V.
12.3. Apotex Inc.
12.4. Blueprint Medicines Corporation
12.5. CStone Pharmaceuticals
12.6. Viatris Inc.
12.7. Cigna HealthCare
12.8. Ralington Pharma
12.9. Enzo Life Sciences, Inc.
12.10. Genentech USA, Inc.
13. Appendix
13.1. About Us and Services
13.2. Contact Us